Committee members including Chairman Greg Walden (R-OR) agreed to slow down the passing of the act, which seeks to remove barriers regarding competition of generic drugs.
“We neither support nor oppose (the bill),” Joseph Hill, director of the American Society of Health-System Pharmacists' government relations division, said in a news release.
The committee is looking for the U.S. Food and Drug Administration to address the needs to regulate competition in the drug market in an attempt to create a fairer market.
Alerts Sign-up